Thyroid Hormone Receptors and Cancer

Overview

Journal Biochim Biophys Acta

Specialties Biochemistry
Biophysics

Date 2012 Apr 18

PMID 22507269

Citations 55

Authors

Won Gu Kim

Sheue-Yann Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Thyroid hormone receptors (TRs) are ligand-dependent transcription factors that mediate the actions of the thyroid hormone (T3) in development, growth, and differentiation. The THRA and THRB genes encode several TR isoforms that express in a tissue- and development-dependent manner. In the past decades, a significant advance has been made in the understanding of TR actions in maintaining normal cellular functions. However, the roles of TRs in human cancer are less well understood. The reduced expression of TRs because of hypermethylation, or deletion of TR genes found in human cancers suggests that TRs could function as tumor suppressors. A close association of somatic mutations of TRs with human cancers further supports the notion that the loss of normal functions of TR could lead to uncontrolled growth and loss of cell differentiation.

Scope Of Review: In line with the findings from association studies in human cancers, mice deficient in total functional TRs (Thra1(-/-)Thrb(-/-) mice) or with a targeted homozygous mutation of the Thrb gene (denoted PV; Thrb(PV/PV) mice) spontaneously develop metastatic thyroid carcinoma. This review will examine the evidence learned from these genetically engineered mice that provided strong evidence to support the critical role of TRs in human cancer.

Major Conclusions: Loss of normal functions of TR by deletion or by mutations could contribute to cancer development, progression and metastasis.

General Significance: Novel mechanistic insights are revealed in how aberrant TR activities lead to carcinogenesis. Mouse models of thyroid cancer provide opportunities to identify molecular targets as potential treatment modalities. This article is part of a Special Issue entitled Thyroid hormone signalling.

Citing Articles

The thyroid hormone activating enzyme, DIO2, is a potential pan-cancer biomarker and immunotherapy target.

Nappi A, Miro C, Cicatiello A, Sagliocchi S, Acampora L, Restolfer F J Endocrinol Invest. 2025; .

PMID: 39821172 DOI: 10.1007/s40618-024-02526-9.

Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer.

Hantusch B, Kenner L, Stanulovic V, Hoogenkamp M, Brown G Int J Mol Sci. 2024; 25(17).

PMID: 39273194 PMC: 11394715. DOI: 10.3390/ijms25179245.

Transcription factor STAT4 counteracts radiotherapy resistance in breast carcinoma cells by activating the MALAT1/miR-21-5p/THRB regulatory network.

Guo L, Ding G, Ba Y, Tan B, Tian L, Wang K Am J Cancer Res. 2024; 14(4):1501-1522.

PMID: 38726265 PMC: 11076251. DOI: 10.62347/VSJU7227.

Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications.

Wang Z, Wang H, Bu C, Meng B, Mu Y, Gao S Eur J Clin Pharmacol. 2024; 80(6):827-838.

PMID: 38483545 DOI: 10.1007/s00228-024-03626-4.

Exploring the Relationship between -MS2 Variants and Susceptibility to Bladder Cancer.

Jeong M, Mun J, Yang G, Kim M, Lee S, Choi Y Genes (Basel). 2024; 15(1).

PMID: 38254939 PMC: 10815179. DOI: 10.3390/genes15010050.

References

Iwasaki Y, Sunaga N, Tomizawa Y, Imai H, Iijima H, Yanagitani N . Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer. Ann Surg Oncol. 2010; 17(8):2222-8. DOI: 10.1245/s10434-010-0956-9. View

Kim W, Guigon C, Fozzatti L, Park J, Lu C, Willingham M . SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res. 2012; 18(5):1281-90. PMC: 3294177. DOI: 10.1158/1078-0432.CCR-11-2892. View

Ying H, Furuya F, Zhao L, Araki O, West B, Hanover J . Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest. 2006; 116(11):2972-84. PMC: 1592548. DOI: 10.1172/JCI28598. View

Liu J, Stevens J, Rote C, Yost H, Hu Y, Neufeld K . Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell. 2001; 7(5):927-36. DOI: 10.1016/s1097-2765(01)00241-6. View

Yu R, Lu W, Chen J, McCabe C, Melmed S . Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology. 2003; 144(11):4991-8. DOI: 10.1210/en.2003-0305. View

Guigon C, Cheng S . Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol. 2009; 308(1-2):63-9. PMC: 2744088. DOI: 10.1016/j.mce.2009.01.007. View

Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter T . Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci U S A. 2000; 97(24):13209-14. PMC: 27204. DOI: 10.1073/pnas.230285997. View

Chen L, Matsumura K, Deng G, Kurisu W, Ljung B, Lerman M . Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res. 1994; 54(11):3021-4. View

Dobson M, Diallo-Krou E, Grachtchouk V, Yu J, Colby L, Wilkinson J . Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. Endocrinology. 2011; 152(11):4455-65. PMC: 3199014. DOI: 10.1210/en.2011-1178. View

10.

Astapova I, Vella K, Ramadoss P, A Holtz K, Rodwin B, Liao X . The nuclear receptor corepressor (NCoR) controls thyroid hormone sensitivity and the set point of the hypothalamic-pituitary-thyroid axis. Mol Endocrinol. 2011; 25(2):212-24. PMC: 3386544. DOI: 10.1210/me.2010-0462. View

11.

Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H . Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. 1988; 2(3):283-7. View

12.

Mitra S, Hanson D, Schlaepfer D . Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005; 6(1):56-68. DOI: 10.1038/nrm1549. View

13.

Zimonjic D, Kato Y, Ying H, Popescu N, Cheng S . Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice. Cancer Genet Cytogenet. 2005; 161(2):104-9. DOI: 10.1016/j.cancergencyto.2005.02.007. View

14.

Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng S, Nauman J . Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab. 2002; 87(3):1120-8. DOI: 10.1210/jcem.87.3.8296. View

15.

Sisley K, Curtis D, Rennie I, Rees R . Loss of heterozygosity of the thyroid hormone receptor B in posterior uveal melanoma. Melanoma Res. 1993; 3(6):457-61. DOI: 10.1097/00008390-199311000-00009. View

16.

Yu R, Heaney A, Lu W, Chen J, Melmed S . Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem. 2000; 275(47):36502-5. DOI: 10.1074/jbc.C000546200. View

17.

Zhu X, Zhao L, Willingham M, Cheng S . Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene. 2010; 29(13):1909-19. PMC: 3443884. DOI: 10.1038/onc.2009.476. View

18.

Owens L, Xu L, Dent G, Yang X, Sturge G, Craven R . Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol. 1996; 3(1):100-5. DOI: 10.1007/BF02409059. View

19.

Joseph B, Ji M, Liu D, Hou P, Xing M . Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab. 2007; 92(12):4766-70. DOI: 10.1210/jc.2007-0812. View

20.

Lin K, Shieh H, Chen S, Hsu H . Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog. 1999; 26(1):53-61. DOI: 10.1002/(sici)1098-2744(199909)26:1<53::aid-mc7>3.0.co;2-z. View